- Home
- KNDI vs CHRS Comparison
KNDI vs CHRS Comparison
Compare KNDI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNDI
- CHRS
- Stock Information
- Founded
- KNDI 2002
- CHRS 2010
- Country
- KNDI China
- CHRS United States
- Employees
- KNDI N/A
- CHRS N/A
- Industry
- KNDI Auto Manufacturing
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KNDI Consumer Discretionary
- CHRS Health Care
- Exchange
- KNDI Nasdaq
- CHRS Nasdaq
- Market Cap
- KNDI 96.3M
- CHRS 84.2M
- IPO Year
- KNDI N/A
- CHRS 2014
- Fundamental
- Price
- KNDI $1.13
- CHRS $0.82
- Analyst Decision
- KNDI
- CHRS Buy
- Analyst Count
- KNDI 0
- CHRS 3
- Target Price
- KNDI N/A
- CHRS $4.68
- AVG Volume (30 Days)
- KNDI 97.2K
- CHRS 1.3M
- Earning Date
- KNDI 08-15-2025
- CHRS 08-07-2025
- Dividend Yield
- KNDI N/A
- CHRS N/A
- EPS Growth
- KNDI N/A
- CHRS N/A
- EPS
- KNDI N/A
- CHRS N/A
- Revenue
- KNDI $127,569,613.00
- CHRS $272,251,000.00
- Revenue This Year
- KNDI N/A
- CHRS N/A
- Revenue Next Year
- KNDI N/A
- CHRS $106.56
- P/E Ratio
- KNDI N/A
- CHRS $1.90
- Revenue Growth
- KNDI 3.21
- CHRS 19.87
- 52 Week Low
- KNDI $0.89
- CHRS $0.66
- 52 Week High
- KNDI $2.12
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- KNDI 51.22
- CHRS 53.65
- Support Level
- KNDI $1.06
- CHRS $0.72
- Resistance Level
- KNDI $1.16
- CHRS $0.77
- Average True Range (ATR)
- KNDI 0.07
- CHRS 0.04
- MACD
- KNDI 0.00
- CHRS 0.01
- Stochastic Oscillator
- KNDI 57.14
- CHRS 91.74
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.